Utility of pharmacogenomic testing in predicting intolerance to BTK inhibitors
Publication
, Conference
Basher, F; Scobie, MR; Kelley, MJ; Voora, D; Friedman, DR
Published in: JOURNAL OF CLINICAL ONCOLOGY
2023
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Basher, F., Scobie, M. R., Kelley, M. J., Voora, D., & Friedman, D. R. (2023). Utility of pharmacogenomic testing in predicting intolerance to BTK inhibitors. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).
Basher, Fahmin, Micaela R. Scobie, Michael J. Kelley, Deepak Voora, and Daphne Ruth Friedman. “Utility of pharmacogenomic testing in predicting intolerance to BTK inhibitors.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.
Basher F, Scobie MR, Kelley MJ, Voora D, Friedman DR. Utility of pharmacogenomic testing in predicting intolerance to BTK inhibitors. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.
Basher, Fahmin, et al. “Utility of pharmacogenomic testing in predicting intolerance to BTK inhibitors.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.
Basher F, Scobie MR, Kelley MJ, Voora D, Friedman DR. Utility of pharmacogenomic testing in predicting intolerance to BTK inhibitors. JOURNAL OF CLINICAL ONCOLOGY. 2023.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences